参考文献/References:
[1].Essien UR,Kornej J,Johnson AE,et al.Social determinants of atrial fibrillation [J].Nat Rev Cardiol,2021,18(11):763-773.
[2].Du X,Guo L,Xia S,et al.Atrial fibrillation prevalence,awareness and management in a nationwide survey of adults in China[J].Heart,2021,107(7):535-541.
[3].Burdett P,Lip GYH.Atrial fibrillation in the UK:predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs[J].Eur Heart J Qual Care Clin Outcomes,2022,8(2):187-194.
[4].Wijesurendra RS,Casadei B.Mechanisms of atrial fibrillation[J].Heart,2019,105(24):1860-1867.
[5].Xia W,Li X,Wu Q,et al. The importance of caveolin as a target in the prevention and treatment of diabetic cardiomyopathy[J]. Front Immunol,2022,13:951381.
[6].Chen YC,Voskoboinik A,Gerche A,et al.Prevention of pathological atrial remodeling and atrial fibrillation:JACC state-of-the-art review [J].J Am Coll Cardiol,2021,77(22):2846-2864.
[7].Tribulova N,Egan Benova T,Szeiffova Bacova B,et al.New aspects of pathogenesis of atrial fibrillation: remodelling of intercalated discs[J].J Physiol Pharmacol,2015,66(5):625-634.
[8].Landstrom AP,Dobrev D,Wehrens XHT.Calcium signaling and cardiac arrhythmias[J].Circ Res,2017,120(12):1969-1993.
[9].Heijman J,Muna AP,Veleva T,et al.Atrial myocyte NLRP3/CaMKII Nexus forms a substrate for postoperative atrial fibrillation [J].Circ Res,2020,127(8):1036-1055.
[10].Zhou B,Caudal A,Tang X,et al.Upregulation of mitochondrial ATPase inhibitory factor 1 (ATPIF1) mediates increased glycolysis in mouse hearts [J].J Clin Invest,2022,132(10):e155333.
[11].Guan D,Xiong Y,Borck PC,et al.Diet-induced circadian enhancer remodeling synchronizes opposing hepatic lipid metabolic processes [J].Cell,2018,174(4):831-842.e12.
[12].Emelyanova L,Ashary Z,Cosic M,et al.Selective downregulation of mitochondrial electron transport chain activity and increased oxidative stress in human atrial fibrillation [J].Am J Physiol Heart Circ Physiol,2016,311(1):H54-63.
[13].Davogustto G,Dillon W,Salazar R,et al. The Warburg effect in the heart：increased glucose metabolism drives car-diomyocyte hypertrophy in response to adrenergic stimulation[J]. J Am Coll Cardiol,2018,71(11):A802-812.14.
[14].Hu HJ,Zhang C,Tang ZH,et al. Regulating the Warburg effect on metabolic stress and myocardial fibrosis remodeling and atrial intracardiac waveform activity induced by atrial fibrillation[J].Biochem Biophys Res Commun,2019,516(3):653-660.
[15].Garbincius JF,Elrod JW.Mitochondrial calcium exchange in physiology and disease[J].Physiol Rev,2022,102(2):893-992.
[16].Kummer E,Ban N.Mechanisms and regulation of protein synthesis in mitochondria[J].Nat Rev Mol Cell Biol,2021,22(5):307-325.
[17].Wiersma M,van Marion DMS,Wüst RCI,et al.Mitochondrial dysfunction underlies cardiomyocyte remodeling in experimental and clinical atrial fibrillation [J].Cells,2019,8(10):1202.
[18].Foster MN,Coetzee WA.KATP channels in the cardiovascular system [J] .Physiol Rev,2016,96(1):177-252.
[19].Brown SM,Larsen NK,Thankam FG,et al.Fetal cardiomyocyte phenotype ,ketone body metabolism,and mitochondrial dysfunction in the pathology of atrial fibrillation[J].Mol Cell Biochem,2021,476(2):1165-1178.
[20].Zhang D,Wu CT,Qi X,et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation [J].Circulation,2014,129(3):346-358.
[21].Boyman L,Karbowski M,Lederer WJ.Regulation of mitochondrial ATP production:Ca2+ signaling and quality control [J].Trends Mol Med,2020,26(1):21-39.
[22].Montaigne D,Butruille L,Staels B.PPAR control of metabolism and cardiovascular functions[J].Nat Rev Cardiol,2021,18(12):809-823.
[23].Pol CJ,Lieu M,Drosatos K.PPARs: protectors or opponents of myocardial function?[J].PPAR Res,2015,2015:835985.
[24].Legchenko E,Chouvarine P,Borchert P,et al.PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation [J].Sci Transl Med,2018,10(438):eaao0303.
[25].Yan XL,Wang YY,Yu ZF,et al. Peroxisome proliferator-activated receptor-gamma activation attenuates diabetic cardiomyopathy via regulation of the TGF-β/ERK pathway and epithelial-to-mesenchymal transition [J].Life Sci,2018,213:269-278.
[26].Taylor CT,Scholz CC.The effect of HIF on metabolism and immunity[J].Nat Rev Nephrol,2022,18(9):573-587.
[27].Ambrose LJA,Abd-Jamil AH,Gomes RSM,et al.Investigating mitochondrial metabolism in contracting HL-1 cardiomyocytes following hypoxia and pharmacological HIF activation identifies HIF-dependent and independent mechanisms of regulation [J].J Cardiovasc Pharmacol Ther,2014,19(6):574-585.
[28].Suffee N,Baptista E,Piquereau J,et al. Impacts of a high-fat diet on the metabolic profile and the phenotype of atrial myocardium in mice [J].Cardiovasc Res,2022,118(15):3126-3139.
[29].Lim SA,Moon Y,Shin MH,et al.Hypoxia-driven HIF-1α activation reprograms pre-activated NK cells towards highly potent effector phenotypes via ERK/STAT3 pathways [J].Cancers (Basel),2021,13(8):1904.
[30].Krishnan J,Suter M,Windak R,et al.Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy [J].Cell Metab,2009,9(6):512-524.
[31].Liu Y,Zhang Q,Yang L,et al.Viametformin attenuates cardiac hypertrophy the HIF-1α/PPAR-γ signaling pathway in high-fat diet rats[J].Front Pharmacol,2022,13:919202.
[32].Ban JJ,Ruthenborg RJ,Cho KW,et al.Regulation of obesity and insulin resistance by hypoxia-inducible factors [J].Hypoxia (Auckl),2014,2:171-183.
[33].Hoong CWS,Chua MWJ.SGLT2 inhibitors as calorie restriction mimetics:insights on longevity pathways and age-related diseases[J].Endocrinology,2021,162(8):bqab079.
[34].Liao Hung-Wei,Saver Jeffrey L,Wu Yi-Ling et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.[J] .BMJ Open, 2017, 7: e013927.
[35].Zhang Z,Zhang X,Meng L,et al.Pioglitazone inhibits diabetes-induced atrial mitochondrial oxidative stress and improves mitochondrial biogenesis ,dynamics,and function through the PPAR-γ/PGC-1α signaling pathway[J].Front Pharmacol,2021,12:658362.
[36].Zhang Zhiwei,Zhang Xiaowei,Korantzopoulos Panagiotis et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis.[J] .BMC Cardiovasc Disord, 2017, 17: 96.
[37].Liu C,Liu R,Fu H,et al.Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits [J].Cardiovasc Ther,2017,35(5).DOI:10.1111/1755-5922.12284.
[38].Ploeg MC,Munts C,Prinzen FW,et al.Piezo1 mechanosensitive ion channel mediates stretch-induced Nppb expression in adult rat cardiac fibroblasts [J].Cells,2021,10(7):1745.
[39].Fernandez-Boyanapalli RF,Frasch SC,Thomas SM,et al.Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease[J].J Allergy Clin Immunol,2015,135(2):517-527.e12.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(10):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(10):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(10):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(10):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(10):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(10):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]